Utibapril

This classification denotes an antihypertensive agent with the molecular formula C22H31N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87I5H747BC, chemically known as 1,3,4-thiadiazole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-2,3-dihydro-, (2s-(2r*,3(r*(r*))))- but generally known as utibapril, which bears US NIH Compound Identifier 60359. European Medicines Agency schedules Utibapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11391MIG. The term UTIBAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). UTIBAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule utibapril under HS 29349990 and SITC 51579. As of Q4 2014, UTIBAPRIL remains the US FDA Preferred Term for this commodity. Utibapril bears US NLM identifiers UMLS ID C0082621 and NCI Concept Code C81524. SMILES: S1C(=NN(C1C(=O)O)C(=O)C(NC(CCc1ccccc1)C(=O)OCC)C)C(C)(C)C.